Article
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC.
Science translational medicine - 17 Jun 2020
Goswami Sangeeta, Chen Yulong, Anandhan Swetha, Szabo Peter M, Basu Sreyashi, Blando Jorge M, Liu Wenbin, Zhang Jan, Natarajan Seanu Meena, Xiong Liangwen, Guan Baoxiang, Yadav Shalini Singh, Saci Abdel, Allison James P, Galsky Matthew D, Sharma Padmanee
Abstract excerpt
Immune checkpoint therapy (ICT) can produce durable antitumor responses in metastatic urothelial carcinoma (mUCC); however, the responses are not universal. Despite multiple approvals of ICT in mUCC, we lack predictive biomarkers to guide patient selection. The identification of biomarkers may require interrogation of both the tumor mutational status and the immune microenvironment. Through multi-platform...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.